SCHEDULE: FMR LLC Discloses 7.2% Stake in Veracyte Inc.

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 7.2% of Veracyte Inc.'s common stock as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, through various subsidiaries and affiliates, beneficially own 5,688,209.19 shares of Veracyte Inc. common stock.
• This ownership represents 7.2% of the total outstanding common stock of Veracyte Inc.
• FMR LLC holds sole voting power over 5,682,465.00 shares and sole dispositive power over 5,688,209.19 shares.
• Abigail P. Johnson, as a director, chairman, and CEO of FMR LLC, is deemed to beneficially own the same aggregate amount of shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Veracyte Inc.
• Fidelity Management & Research Company LLC, a subsidiary of FMR LLC, beneficially owns 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant stake by a reputable institutional investor like FMR LLC typically signals confidence in the company's value and future prospects, without indicating an intent to disrupt management.

Positives

• A significant institutional investor like FMR LLC holding a 7.2% stake can signal confidence in Veracyte Inc.'s long-term prospects.
• The acquisition of shares in the ordinary course of business suggests a strategic investment rather than an activist play, potentially indicating stability.

Risks

• The concentration of a significant portion of voting power (7.2%) with a single institutional holder, FMR LLC, could potentially influence future corporate decisions, even if not explicitly stated as an intent to control.
• Changes in FMR LLC's investment strategy or portfolio rebalancing could lead to large-scale selling of Veracyte Inc. shares, potentially impacting market price.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

StockSavvy.ai notes that a significant stake by a major asset manager like FMR LLC in a healthcare technology company like Veracyte Inc. often reflects a belief in the company's long-term growth potential within the diagnostics and precision medicine sector. This type of institutional investment can provide a vote of confidence, distinguishing Veracyte from smaller, less established players in a competitive market.

Comparison to Industry Standards

• A 7.2% beneficial ownership stake by a single institutional entity like FMR LLC is a substantial position, often placing them among the top shareholders. For example, similar large institutional holdings are seen in companies like Illumina (ILMN) or Guardant Health (GH), where major asset managers frequently hold significant, but non-controlling, stakes, indicating a long-term investment thesis in the genomics and oncology diagnostics space.
• This level of ownership is typical for passive institutional investors who aim for portfolio diversification and long-term capital appreciation without seeking active control, contrasting with activist investors who might acquire similar stakes to push for specific corporate changes.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may instill confidence among existing shareholders and attract new investors, potentially stabilizing or positively influencing the stock price.
• Management: Management may view this as a vote of confidence in their strategy, though they will be aware of a large shareholder's potential influence.

Key Dates

Recommendation

The disclosure of a substantial 7.2% stake by FMR LLC in Veracyte Inc. is generally a positive signal, indicating institutional confidence. However, as a Schedule 13G filing, it primarily reports a passive investment without detailing new strategic initiatives or financial performance. Therefore, while the institutional backing is reassuring, a 'hold' recommendation is appropriate as it doesn't provide new fundamental data to warrant a 'buy' or 'sell' action, but rather confirms a significant long-term investor's position.

Keywords

Veracyte Inc, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Healthcare Technology, Biotechnology